FIVE DREADED WORDS

We didn’t get it all.

We can improve the Precision of Cancer Resection

bladder2

Transurethral Resection of Bladder Tumer (TURBT)

0 %
of TURBT resections are incomplete, contributing to higher risk o residual disease, early recurrence and incereased mortality ¹
breast_blue

Breast Conservation Surgeries (BCS)

up to

0 %
15-35% of BCS lumpectomies require a second surgery which often presents increased risk of complications ²
bladder_blue

Radical Prostatectomies (RP)

0 %
of RP procedures result in positive surgical margins, leading to a 2 to 3 fold increase in risk of biochemical recurrence ³
1. Quality of diagnostic staging in patients with bladder cancer: A process‐outcomes link. K Chamie, et al. 3, 2015, Cancer, Vol. 121
2. A randomized, controlled trial of Cavity Shave margins in breast cancer. Chagpar, A. B et al. (2015). New England Journal of Medicine, 373(6)
3. Frequency of Positive Surgical Margin at Prostatectomy and Its Effect on Patient Outcome. K. Iczkowski, M. Scott. Prostate Cancer, Vol. 2011
OUR MISSION
The development of AI-powered cancer imaging technology that delivers real-time cancer tissue visualization, enabling more precise intraoperative decisions and improving patient outcomes.

CytoVeris is aligned with the OR of the future

REAL-TIME

green clock
Easy to interpret tools to visualize cancer tissue in real-time during surgery and enable faster decisions

DATA

The future of surgery is DIGITAL – real-time information to surgeons during surgery

PERSONALIZED

Personalized
Accurate margin data allows customization of the surgical procedure to each patient’s needs

ROBOTICS

Platform technology presents ability to integrate TumorMAP™ imaging into robotics surgical procedures

Personalized cancer resection

better intraoperative insights – increased precision

Enabling SMARTER, more EFFICIENT, and more EFFECTIVE surgical visualization

The Tumor Margin Assessment and Profiling System,  TumorMAP™ is a multispectral imaging (MSI), Ultra high-definition (UHD), real-time intraoperative cancer imaging solution. TumorMAP produces an ultra-violet-excited autofluorescence image that enables surgeons to visually assess tissue that is indicative of cancer, based on changes in metabolism and tissue microstructure between healthy and unhealthy tissues.

All without the use of an imaging agent

INCREASED PRECISION

intraoperative tissue insights increase margin accuracy

SEAMLESS FIT  w/WORKFLOW

intra-operative efficiency require fewer resources

COST SAVINGS

of secondary operations & additional treatments

better outcomes

fewer complications, re-operations, radiation therapy, better functional outcomes

>> CLICK HERE  TO LEARN MORE ABOUT ONCOSIGHT AI

OncoSIGHT AI™ is a proprietary, next generation tissue characterization algorithm that provides a safer, smarter and more reliable visualization of cancerous tissue.

CytoVeris’ Platform Technology, TumorMAP™ powered by OncoSight AI™, relies on the intersection of natural characteristics of tissue and AI, and is in development to make a difference for patients across multiple disease areas.

Indication

Pre-clinical research

OncoSIGHT AI training
OncoSIGHT AI validation

Feasibility Study

Pivotal Study

FDA Approval

breast
bladder
liver

“CYTOVERIS NAMED "MURPHY'S INNOVATOR OF THE MONTH"

CytoVeris is a medical device company developing optical smart cancer imaging technologies designed to improve the clinical outcomes of patients undergoing certain cancer removal procedures by using enhanced clinical decision-making during surgery.